SABCS: T-DM1 Cuts Recurrent Invasive HER2 & #43; Breast CA Risk

WEDNESDAY, Dec. 5, 2018 -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news